GET DAILY SIGNALSZoetis (ZTS) Rebounds +16% in 30 Days: Recovery Signals Emerge
Key Takeaways
- Zoetis (ZTS) climbed roughly 16% over the trailing 30 days, rising from about $71.41 to $82.99, after touching a 52-week low near $68.77 in early October.
- The rebound follows a prolonged 2026 decline; shares remain down more than 30% year to date and well below the 52-week high near $148.
- Over the last quarter, the stock recovered from its October trough to a net gain of approximately 9%, signaling improving near-term sentiment.
- Analyst activity has supported the move, including J.P. Morgan's maintained Buy rating and UBS's raised price target, ahead of third-quarter results.
- Q3 earnings, expected on November 5, carry consensus estimates of $1.51 per share and $2.30 billion in revenue, both lower year over year.
- Broader drivers include pet-owner demand trends, companion-animal competition, and relative strength in the livestock portfolio.
Company Overview and Market Position
Zoetis is the world's leading animal health company, developing and selling medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. The company operates across the United States and international markets, serving veterinarians, livestock producers, and pet owners in more than 100 countries. Its portfolio includes well-known franchises such as the Simparica parasiticides, Apoquel and Cytopoint for dermatology, and the ProHeart line, alongside livestock products for cattle, poultry, swine, and fish. Investors follow ZTS for its diversified revenue base, strong R&D pipeline, and leadership in an animal health industry that tends to be less cyclical than human pharmaceuticals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ZTS advanced from a closing price of $71.41 on October 5 to $82.99 on November 3, a gain of about 16.2%. The move marked a decisive reversal after the stock established a 52-week low near $68.77 in early October, meaning the shares recovered roughly 21% off that intraday trough.
The last quarter tells a more mixed story. Entering August, ZTS traded near $76, then slid through September and into early October before staging a sharp rebound. From an early-August close of roughly $76 to the current level near $83, the stock posted a net quarterly gain of about 9% — a recovery that followed a multi-month drawdown rather than a steady climb. From what I see, this pattern suggests the recent bounce may be more technical than fundamental at this stage.
Factors Behind the Recent 30-Day Advance
The recent advance appears driven by a combination of technical, fundamental, and sentiment-related factors. After a steep 2026 selloff left the stock trading at its lowest level in over a year, ZTS reached deeply oversold conditions, setting the stage for a relief rally as buyers stepped in near the October lows.
Analyst actions reinforced the move. J.P. Morgan maintained a Buy rating with a $115 price target in mid-October, while UBS raised its price target to $85 in late October. At the same time, Goldman Sachs initiated coverage with a Hold rating and a $74 target, reflecting a more cautious view and highlighting the divergence of opinion among institutions. I’m watching this closely because these conflicting targets could keep volatility elevated.
Anticipation of third-quarter earnings also contributed. With results scheduled for November 5 and a history of beating consensus estimates in seven of the last eight quarters, some investors positioned ahead of the release. Positive earnings-revision momentum that began in early October further supported the rebound.
Quarterly Performance and Underlying Drivers
The quarterly narrative centers on a recovery from a prolonged decline. Through 2026, Zoetis shares fell sharply as investors weighed softer companion-animal demand, increased competition, and pressure on products such as the osteoarthritis treatments Librela and Solensia in the U.S. market. These headwinds drove the stock from its 52-week high near $148 to a low near $68.77 by early October.
The fourth-quarter-to-date turnaround reflects stabilization in sentiment rather than a single catalyst. Strength in parasiticides and dermatology products, continued livestock-portfolio momentum, and a recent FDA approval for the injectable antibiotic Convenia RTU for dogs provided incremental positives. Combined with oversold technical conditions and selective analyst support, these factors helped the stock reclaim a meaningful portion of its losses. One thing that stands out is how the livestock side has held up better than the companion-animal segment.
What to Watch in the Near Term
Investors will be watching several factors in the near term. The upcoming third-quarter earnings report and management guidance will be pivotal, particularly commentary on U.S. companion-animal demand, price sensitivity, and the competitive landscape. Consensus expectations call for lower earnings and revenue year over year, so the market's reaction will likely hinge on guidance and margin commentary rather than headline results alone.
Beyond earnings, key items to monitor include pet-owner spending trends, adoption and sales momentum for parasiticides and dermatology products, the commercialization of recently approved treatments, and livestock-market conditions. Macroeconomic factors such as consumer discretionary spending and veterinary-visit volumes may also influence demand. Analysts remain divided, with price targets ranging widely, reflecting ongoing uncertainty about the pace of the company's recovery. In my view, the earnings call will likely set the tone for the rest of the year.
Using Tickeron AI Tools in My Research
I often rely on Tickeron’s Trending AI Robots to get a sense of how automated systems are positioned on names like ZTS. The page curates top-performing bots across strategies and timeframes, which helps me cross-check my own analysis without having to review every signal manually. It’s a practical way to see algorithmic sentiment alongside traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZTS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ZTS turned positive on October 06, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on ZTS as a result. In 45 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
ZTS moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 142 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 98 of 188 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ZTS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ZTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.894) is normal, around the industry mean (8.179). P/E Ratio (13.538) is within average values for comparable stocks, (-0.806). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.202). Dividend Yield (0.026) settles around the average of (0.046) among similar stocks. P/S Ratio (3.299) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pet medication company
Industry PharmaceuticalsGeneric
Advertisement